Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) EBT Margin (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed EBT Margin for 14 consecutive years, with 69.79% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin fell 7215.0% to 69.79% in Q4 2025 year-over-year; TTM through Dec 2025 was 38.7%, a 3853.0% decrease, with the full-year FY2025 number at 20.71%, down 478.0% from a year prior.
  • EBT Margin was 69.79% for Q4 2025 at Aytu Biopharma, down from 14.15% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 20.69% in Q1 2025 to a low of 219.32% in Q1 2022.
  • A 5-year average of 42.15% and a median of 25.47% in 2022 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: soared 18765bps in 2023, then crashed -12693bps in 2025.
  • Aytu Biopharma's EBT Margin stood at 49.95% in 2021, then skyrocketed by 49bps to 25.47% in 2022, then skyrocketed by 129bps to 7.46% in 2023, then tumbled by -68bps to 2.35% in 2024, then crashed by -3064bps to 69.79% in 2025.
  • Per Business Quant, the three most recent readings for AYTU's EBT Margin are 69.79% (Q4 2025), 14.15% (Q3 2025), and 128.46% (Q2 2025).